Evidence map›Paper›PMID 33402463›Full record

ArticleIn vivo (Athens, Greece)

Correlation Between Onco-suppressors PTEN and NM23 and Clinical Outcome in Patients With T1 Breast Cancer.

Luciano Izzo, Daniela Messineo, Pierfrancesco DI Cello, Virgilio Nicolanti, Antonio Sterpetti, Sara Izzo, Paolo Izzo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The effects of the tumor suppressor geneTranslational cancer research · 2023
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Luciano IzzoPietro Valdoni Department of Surgery, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy; luciano.izzo@uniroma1.it.
Daniela MessineoDepartment of Radiological Sciences, Oncology and Pathology, Sapienza University, Rome, Italy.
Pierfrancesco DI CelloUOC Chirurgia Generale Frosinone-Alatri presso ASL Frosinone, Frosinone, Italy.
Virgilio NicolantiPietro Valdoni Department of Surgery, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Antonio SterpettiPietro Valdoni Department of Surgery, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Sara IzzoMultidisciplinary Department of Medical-Surgical and Dental Specialties, Plastic Surgery Unit, Luigi Vanvitelli University of Campania, Naples, Italy.
Paolo IzzoPietro Valdoni Department of Surgery, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of the present work was to evaluate the prognostic significance in patients with T1 breast cancer of tissue expression of the two oncosuppressors phosphatase and tensin homolog (PTEN) and non-metastatic clone 23 (NM23) as detected by immunohistochemistry. MATERIALS AND

methodsWe prospectively analyzed 62 patients who underwent surgery for a T1 stage breast cancer. Expression of PTEN and NM23 was tested for correlation with clinical characteristics and clinical outcome.

resultsOf the 62 patients considered for our study, 16 underwent mastectomy and 46 underwent conservative surgical treatment. The surgery was considered radical (R0) in all cases described. PTEN and NM23 expression was higher in patients with no lymph node metastases and no recurrent cancer at a mean follow-up of 36 months (range=6-48 months). This correlation was more evident when both PTNE and NM23 expression were highly expressed (p<0.0001).

conclusionLow or lack of PTEN and NM23 immunohistochemical expression in cancer tissue is a risk factor for lymph node involvement and recurrent disease. It may represent a valid prognostic factor in planning therapy in patients who had surgery for T1 breast cancer.

Indexed as

Breast NeoplasmsNucleoside-Diphosphate KinaseBiomarkers, TumorFemaleHumansMastectomyNeoplasm Recurrence, LocalNM23 Nucleoside Diphosphate KinasesPrognosisPTEN PhosphohydrolaseBiomarkers, TumorNM23 Nucleoside Diphosphate KinasesNME1 protein, humanNucleoside-Diphosphate KinasePTEN PhosphohydrolasePTEN protein, humanbreast cancerHER2NM23PTEN

Identifiers

PMID33402463
PMCPMC7880771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.